Northwest Biotherapeutics Reports Officer and Director Changes
Ticker: NWBO · Form: 8-K · Filed: 2024-03-14T00:00:00.000Z
Sentiment: neutral
Topics: management-change, corporate-governance
Related Tickers: NWBO
TL;DR
NWBO just shook up its board and exec team, expect new comp plans.
AI Summary
Northwest Biotherapeutics, Inc. filed an 8-K on March 14, 2024, reporting changes effective March 8, 2024. These changes include the departure of directors or certain officers, the election of directors, and the appointment of certain officers, along with details on compensatory arrangements for these officers.
Why It Matters
Changes in key leadership and compensation structures can signal shifts in company strategy or financial priorities.
Risk Assessment
Risk Level: medium — Changes in executive and director roles can introduce uncertainty regarding future strategy and operational stability.
Key Players & Entities
- Northwest Biotherapeutics, Inc. (company) — Registrant
- March 8, 2024 (date) — Earliest event reported
- March 14, 2024 (date) — Filing date
FAQ
What specific roles were affected by the director or officer changes?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but does not specify the exact roles in this summary.
Were there any specific reasons cited for the departures or appointments?
The provided text does not detail the specific reasons for the departures or appointments of directors and officers.
What are the details of the compensatory arrangements for the newly appointed officers?
The filing mentions compensatory arrangements of certain officers but does not provide specific details within the provided text.
When were these changes officially reported to the SEC?
These changes were reported on an 8-K filing dated March 14, 2024.
What is the principal executive office address for Northwest Biotherapeutics, Inc.?
The principal executive offices are located at 4800 Montgomery Lane, Suite 800, Bethesda, Maryland 20814.
Filing Stats: 427 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-03-14 16:30:25
Key Financial Figures
- $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
Filing Documents
- tm248844d1_8k.htm (8-K) — 21KB
- 0001104659-24-034527.txt ( ) — 187KB
- nwbo-20240308.xsd (EX-101.SCH) — 3KB
- nwbo-20240308_lab.xml (EX-101.LAB) — 33KB
- nwbo-20240308_pre.xml (EX-101.PRE) — 22KB
- tm248844d1_8k_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Retirement of Director Mr. Jerry Jasinowski retired from the Board of Directors of Northwest Biotherapeutics, Inc. on March 8, 2024, after more than a decade of service on the Board. Mr. Jasinowski, aged 85, retired due to health reasons and not due to any disagreement with the Company's operations, policies or practices. The Company thanks Mr. Jasinowski for his many years of service on the Board. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NORTHWEST BIOTHERAPEUTICS, INC. Date: March 14, 2024 By: /s/ Linda Powers Name: Linda Powers Title: Chief Executive Officer and Chairman